Zubin Master
YOU?
Author Swipe
View article: Analysis of <i>P</i> Values in the Abstract Compared With the Main Text of Randomized Controlled Trials and Clinical Trials of Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis
Analysis of <i>P</i> Values in the Abstract Compared With the Main Text of Randomized Controlled Trials and Clinical Trials of Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis Open
Background: Randomized controlled trials (RCTs) and clinical trials (CTs) are critical for evaluating treatment effectiveness, with abstracts serving as the primary source of the study that is read. Purpose: This study explored selective r…
View article: An analysis of stem cell training programs for physicians in the US—A mirage of credibility
An analysis of stem cell training programs for physicians in the US—A mirage of credibility Open
Analyzing stem cell training businesses for United States (US) physicians shows the use of sensationalized marketing language emphasizing profits and growth with many of the instructors affiliated with clinics providing unproven therapies.…
View article: Denoising proton reference dosimetry spectrum using a large area ionization chamber—physical basis and type A uncertainty
Denoising proton reference dosimetry spectrum using a large area ionization chamber—physical basis and type A uncertainty Open
Objective. Reference dosimetry measurement in a pencil beam scanning system can exhibit dose fluctuation due to intra-spill spot positional drift. This results in a noisy reference dosimetry measurement against energy which could introduce…
View article: Descriptions of Scientific Evidence and Uncertainty of Unproven COVID-19 Therapies in US News: Content Analysis Study
Descriptions of Scientific Evidence and Uncertainty of Unproven COVID-19 Therapies in US News: Content Analysis Study Open
Background Politicization and misinformation or disinformation of unproven COVID-19 therapies have resulted in communication challenges in presenting science to the public, especially in times of heightened public trepidation and uncertain…
View article: US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation
US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation Open
The premature marketing of investigational stem cell interventions (SCIs) is a growing market in the US. Several US states have passed legislation to permit and promote unproven and experimental SCIs for individuals with terminal or chroni…
View article: Designing persuasive health education for patients seeking unproven stem cell interventions
Designing persuasive health education for patients seeking unproven stem cell interventions Open
Misinformation among clinics advertising unproven stem cell interventions (SCIs) is pervasive and has resulted in patient and societal harms. Most bioethics commentaries have centered on advancing regulatory approaches to curtail the suppl…
View article: Descriptions of Scientific Evidence and Uncertainty of Unproven COVID-19 Therapies in US News: Content Analysis Study (Preprint)
Descriptions of Scientific Evidence and Uncertainty of Unproven COVID-19 Therapies in US News: Content Analysis Study (Preprint) Open
BACKGROUND Politicization and misinformation or disinformation of unproven COVID-19 therapies have resulted in communication challenges in presenting science to the public, especially in times of heightened public trepidation and uncertai…
View article: ISSCR Education Committee syllabus and learning guide for enhancing stem cell literacy
ISSCR Education Committee syllabus and learning guide for enhancing stem cell literacy Open
The rapidly evolving stem cell field puts much stress on developing educational resources. The ISSCR Education Committee has created a flexible stem cell syllabus rooted in core concepts to facilitate stem cell literacy. The free syllabus …
View article: The Two-Bucket Problem of Unproven Stem Cell Interventions
The Two-Bucket Problem of Unproven Stem Cell Interventions Open
The two-bucket problem of unproven stem cell interventions (SCIs) continues to bifurcate good (ethical) from bad (unethical) practices in the translation of stem cell medicine in ways that divert attention from other salient and challengin…
View article: Opinion: Patient reported motivations for seeking stem cell therapy and considerations for counseling
Opinion: Patient reported motivations for seeking stem cell therapy and considerations for counseling Open
Stem cell therapies occupy a unique place in the American public’s consciousness which has led to excessive enthusiasm over their potential to cure orthopedic conditions. Much has been written about direct-to-consumer marketing of cell the…
View article: Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try
Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try Open
Background For gravely ill patients who have no treatment options and who are ineligible for clinical trials, the US Food and Drug Administration (FDA) established the Expanded Access Program (EAP). Motivated by efforts to weaken FDA regul…
View article: 174 Developing Strategies to Address Health Disparities For First Generation Regenerative Medicine Treatments
174 Developing Strategies to Address Health Disparities For First Generation Regenerative Medicine Treatments Open
OBJECTIVES/GOALS: The objective of this research is to begin documenting barriers to regenerative care to proactively address issues of accessibility and determine and implement interventions in anticipation of equitable care. We will expl…
View article: Patients seeking stem cell therapies—a prospective qualitative analysis from a Regenerative Medicine Consult Service
Patients seeking stem cell therapies—a prospective qualitative analysis from a Regenerative Medicine Consult Service Open
Despite patient demand for stem cell therapies (SCTs) for musculoskeletal conditions, there remains limited research on why patients seek SCTs or their sources of information. We employ three questions into a consult intake form: (1) Why a…
View article: The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation
The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation Open
Introduction: Direct to consumer stem cell and regenerative interventions (SCRIs) for various medical conditions have increased in popularity due to unmet medical needs and the promise of SCRIs to meet those needs. These interventions may …
View article: Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center
Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center Open
The U.S. Food and Drug Administration (FDA) allows patients with serious illnesses to access investigational drugs for “compassionate use” outside of clinical trials through expanded access (EA) Programs. The federal Right-to-Try Act creat…
View article: Physician Responsibility to Discuss Palliative Unproven Therapies With Out-of-Option Patients
Physician Responsibility to Discuss Palliative Unproven Therapies With Out-of-Option Patients Open
This article is referred to by:From “Ought” to “Is”: Surfacing Values in Patient and Family Advocacy in Rare Diseases
View article: How to Handle Co-authorship When Not Everyone’s Research Contributions Make It into the Paper
How to Handle Co-authorship When Not Everyone’s Research Contributions Make It into the Paper Open
While much of the scholarly work on ethics relating to academic authorship examines the fair distribution of authorship credit, none has yet examined situations where a researcher contributes significantly to the project, but whose contrib…
View article: “I Think It’s Been Met With a Shrug:” Oncologists’ Views Toward and Experiences With Right-to-Try
“I Think It’s Been Met With a Shrug:” Oncologists’ Views Toward and Experiences With Right-to-Try Open
Background The federal Right-to-Try (RTT) Act created an alternate regulatory pathway for preapproval access to investigational drugs. A few studies have examined the experiences of physicians with the Food and Drug Administration’s Expand…
View article: Evaluating the FDA Regenerative Medicine Framework: Opportunities for Stakeholders
Evaluating the FDA Regenerative Medicine Framework: Opportunities for Stakeholders Open
There are also a range of cross-cutting interventions that could help to reduce the spread of misinformation surrounding